Screener
BridgeBio Pharma BBIO Reportable Segment — Operating Income (Loss)
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Selling, general and administrative | 163,896 | 106,365 |
| Restructuring, impairment, and related charges | — | 570 |
| Total operating costs and expenses | 300,471 | 221,005 |
| Loss from operations | (105,956) | (104,372) |
| Other income (expense), net: | ||
| Interest income | 6,246 | 5,385 |
| Interest expense | (12,942) | (18,121) |
| Noncash interest expense on deferred royalty obligations (1) | (39,873) | (24,020) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's reportable segment — operating income (loss)?
- BridgeBio Pharma (BBIO) reported reportable segment — operating income (loss) of -$105.96M in Q1 2026.
- How has BridgeBio Pharma's reportable segment — operating income (loss) changed year-over-year?
- BridgeBio Pharma's reportable segment — operating income (loss) decreased by 1.5% year-over-year, from -$104.37M to -$105.96M.
- What does reportable segment — operating income (loss) mean?
- Calculated as segment revenue minus total operating costs and expenses. It measures the core profitability of the segment before accounting for financing or tax impacts.
Ask your AI about BridgeBio Pharma's reportable segment — operating income (loss).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude